Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28038908 | 1.00 | CNR2 (0.41) | CNR2OPRM1OPRK1CNR1MAOA | |
| SCHEMBL15129890 | 1.00 | CNR2 (0.41) | CNR2OPRM1OPRK1CNR1MAOA | |
| SCHEMBL3512916 | 0.84 | GRM2 (0.36) | — | |
| SCHEMBL4254372 | 0.84 | GRM2 (0.36) | — | |
| SCHEMBL6919995 | 0.84 | GRM2 (0.36) | — | |
| SCHEMBL27089331 | 0.81 | DPP4 (0.33) | OPRM1OPRK1 | |
| SCHEMBL27089326 | 0.81 | DPP4 (0.33) | OPRM1OPRK1 | |
| SCHEMBL1493865 | 0.80 | CNR2 (0.42) | CNR2OPRM1OPRK1CNR1 | |
| SCHEMBL1493746 | 0.80 | CNR2 (0.42) | CNR2OPRM1OPRK1CNR1 | |
| SCHEMBL25494519 | 0.80 | OPRM1 (0.42) | CNR2OPRM1OPRK1CNR1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024063648-A1 | Platform and scaffold for FAP targeting agents | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2024-03-28 | — | — | WO | disclosed |
| EP-4342890-A1 | PLATFORM AND SCAFFOLD FOR FAP TARGETING AGENTS | Erasmus University Rotterdam Medical Center (NL) | 2024-03-27 | — | — | EP | disclosed |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | Praxis Biotech LLC (US) | 2023-10-10 | — | — | US | disclosed |
| CN-115160204-A | Fibroblast activation protein inhibitor and preparation method and application thereof | 山东大学 | 2022-10-11 | — | — | CN | disclosed |
| WO-2022017375-A1 | SPECT CONTRAST AGENT FOR FAP-α-SPECIFIC TUMOR DIAGNOSIS | 北京大学 | 2022-01-27 | — | — | WO | disclosed |
| CN-112105354-A | Fibroblast activation protein inhibitor | 普拉西斯生物技术有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-3723753-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019118932-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC (US) | 2019-06-20 | — | — | WO | disclosed |
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Praxis Biotech LLC | 2019-06-20 | — | — | US | disclosed |
| US-20100210838-A1 | FLUOROPYRROLIDINES HAVING DIPEPTIDYL PEPTIDASE ENZYME INHIBITORY ACTIVITY | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | US | disclosed |
| US-7132443-B2 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINEBEECHAM CORPORATION (US) | 2006-11-07 | — | — | US | disclosed |
| US-20050130981-A1 | Compounds | SANOFI-AVENTIS (FR) | 2005-06-16 | — | — | US | disclosed |
| EP-1487807-A2 | NEW COMPOUNDS | Sanofi-Aventis (FR) | 2004-12-22 | — | — | EP | disclosed |
| US-20040242636-A1 | Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity | SMITHKLINE BEECHAM CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20040171848-A1 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-09-02 | — | — | US | disclosed |
| EP-1406873-A2 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1399433-A2 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003074500-A2 | N-AMINOACETYL-PYRROLIDINE-2-CARBONITRILES AND THEIR USE AS DDP-IV INHIBITORS | SANOFI-AVENTIS (FR) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003002531-A2 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002553-A2 | FLUOROPYRROLIDINES AS DIPEPTIDYL PEPTIDASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130981-A1 | Compounds | DPP4, DPP3, DPP7 | CNR2 4329/4885OPRM1 1089/4885OPRK1 847/4885 |
| US-20040242636-A1 | Enzyme inhibitors as antiinflammatory ageents for psoriasis, obesity | DPP4, DPP7, DPP3 | CNR2 4517/4885OPRM1 3065/4885OPRK1 2260/4885 |
| US-20040171848-A1 | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | CNR2 4645/4885OPRM1 3817/4885OPRK1 2871/4885 |
| US-20190185451-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FAP, FIBP, FRS2 | CNR2 4610/4885OPRM1 4873/4885OPRK1 4867/4885 |
| US-20100210838-A1 | FLUOROPYRROLIDINES HAVING DIPEPTIDYL PEPTIDASE ENZYME INHIBITORY ACTIVITY | DPP4, DPP3, DPP7 | CNR2 4756/4885OPRM1 1867/4885OPRK1 1332/4885 |
| US-11780821-B2 | Inhibitors of fibroblast activation protein | FAP, FIBP, FRS2 | CNR2 4610/4885OPRM1 4873/4885OPRK1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.